Defining the role for @entity2682 in the treatment of XXXX : a retrospective study.

@entity1 @entity2682 @entity4254 @entity158 @entity9
The preferred treatment for @entity4254 consists of antiepileptic drugs. Among them, @entity2682 has shown promise in relieving some forms of @entity9 . This retrospective review examined 194 consecutive cases of @entity4254 , many of whom had paroxysmal @entity158 resistant to previous surgical interventions or treatment with multiple medications. Of the 92 who had received a trial of @entity2682 , 43 reported reduction in @entity158 . This benefit was complete in 16, nearly complete in 9, moderate in 12, and partial in 6. Onset of @entity158 relief occurred generally within 1 to 3 weeks, depending on the rate and end point of dose titration. The effective range of stable daily dosing varied from 100 to 2400 mg divided 3 times a day, with a mean of 930 mg. @entity158 relief was sustained in two thirds during a mean follow-up time of 8 months. The fact that @entity2682 was well-tolerated and without serious side effects is an important advantage when prescribing for elderly @entity1 . The present study suggests that @entity2682 can be effective as first or second line treatment of @entity4254 , even in cases resistant to traditional treatment modalities.
